Get started

Press Releases

Delayed 3m

Fastest customizable press release feed in the world.

Signed out · 3-min delay · Sign up for real-time

  • HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
    PR·

    HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine

    — ORPATHYS® plus TAGRISSO® reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO® — — ORPATHYS® plus TAGRISSO® extended median OS by nearly 5 months — — SAFFRON is the first global Phase III trial to show significant progression-free and overall survival benefit in this setting — — Establishes ORPATHYS® plus TAGRISSO® as an important targeted strategy to address MET-driven resistance following progression on prior EGFR TKI treatment —

    $HCM
  • OpenWorld Confirms Dual Listing on Figure OPEN on Track for Q4 2026 Following Stockholder Approval of Blockchain Common Stock
    PR·

    OpenWorld Confirms Dual Listing on Figure OPEN on Track for Q4 2026 Following Stockholder Approval of Blockchain Common Stock

    OpenWorld, Inc. (NASDAQ:OPNW) ("OpenWorld" or the "Company"), a blockchain innovation company advancing real-world asset tokenization, today confirmed that its planned dual listing on Figure’s On-chain Public Equity Network ("Figure OPEN") remains on track to go live in the fourth quarter of 2026. OpenWorld expects to be among the first Nasdaq-listed companies to bring its public equity on-chain, giving institutional and retail investors a new way to hold and trade shares of a U.S. exchange-listed company without leaving the regulatory boundaries of the existing securities framework. The update follows stockholder approval on October 16,

    $FIGR
  • Faraday Future Announces YT Jia’s Investor Weekly Report Rescheduled to October 26; FFR to Hold Listing Ceremony and Investor Day on October 26
    PR·

    Faraday Future Announces YT Jia’s Investor Weekly Report Rescheduled to October 26; FFR to Hold Listing Ceremony and Investor Day on October 26

    This week’s Investor Weekly Report from FF Founder and Global CEO YT Jia has been rescheduled to October 26. FF EAI Robotics Ecosystem Inc. (NASDAQ:FFR) will hold its Listing Ceremony and Investor Day on October 26. FFR management will outline the company’s future strategic direction and business plans and engage with investors in attendance. The full event video will be available at 5:00 p.m. ET on October 26 at: https://www.ff.com/us/ Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) ("Faraday Future," "FF," or the "Company"), a California-based global Embodied AI ("EAI") ecosystem company, today announced that this week’s Investor Weekly Report from FF Founder and Globa

    $FFAI
  • Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
    PR·

    Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026

    Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on Monday, October 26, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast Details Oruka Therapeutics’ live webcast of the EVERLAST-B results will begin on Monday

    $ORKA
  • Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
    PR·

    Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01

    Sone-Ve reduced the risk of death by 53% in 3rd and later-line setting in primary endpoint Consistent data across CLDN18.2 expression levels supports potential for expanded use in up to 60% of patients in this setting Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca’s sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) in 2nd- and later-line Claudin 18.2-positive advanced gastric cancers versus investigator’s choice of therapy. The trial included patients with locally advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, or esophageal a

    $AZN
  • TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
    PR·

    TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

    TAGRISSO plus savolitinib extended median overall survival by nearly five months SAFFRON is first global Phase III trial to show significant progression-free and overall survival benefit in this setting, reinforcing TAGRISSO as backbone therapy across EGFRm lung cancer Positive results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Patients in the trial had tumors with

    $AZN
  • RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
    PR·

    RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

    Responses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase 3 studyData highlight the role of dual-targeting EGFR and MET, key drivers of tumor growth and resistance seen in 80 to 90 percent of

    $JNJ
  • ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
    PR·

    ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026

    44.8% ORR at 6mg/kg dose in late-line CRC patients ARR-217 was generally well-tolerated ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program

    $AVBP
  • Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)
    PR·

    Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)

    Pre-specified and Statistically Powered Key Endpoints Included Progression-free Survival (PFS) and Overall Survival (OS). Although Primary Endpoint of PFS Was Not Met, The Key Secondary Endpoint of OS Was Improved With VAZKEPA/VASCEPA Patients Taking VASCEPA Prior to and Following Liver Resection for CRCLM Were Estimated to Have an Approximately 32% Reduction in the Risk of Death at 5 Years

    $AMRN
  • Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
    PR·

    Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026

    The cohort met its primary endpoint of major pathologic response, with 83% of patients having little or no cancer remaining at surgery in a high-risk, locally advanced population Side effects were mostly mild and manageable, and all 18 patients proceeded to surgery Netherlands Cancer Institute investigators are now enrolling a rectal cancer cohort to evaluate whether a short course of botensilimab and balstilimab can allow patients to avoid surgery Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch repair-deficient (dMMR) colon cancer cohort of NEOASIS, an investigator-initiated pan-tumor study sponsored by th

    $AGEN
  • Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
    PR·

    Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

    Petosemtamab demonstrates encouraging objective response rates (ORRs), with promising depth and durability of response, in first- and second-line metastatic colorectal cancer (mCRC) Data reinforces the ongoing global Phase 3 trials of petosemtamab in mCRC, which are actively enrolling patients Genmab A/S (NASDAQ:GMAB) today announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with FOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC). At a median follow-u

    $GMAB
  • NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
    PR·

    NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development

    Updated Phase 1b dataset provides nearly 18 months of median follow-up and shows the durability of clinical benefit observed with givastomigClinical activity observed across CLDN18.2 expression levels, including in patients with lower-expression tumors not eligible for currently approved CLDN18.2-targeted therapiesTotality of efficacy, safety and long-term follow-up data supports selection of the 8 mg/kg dose for registrational developmentOngoing U.S. Food and Drug Administration (FDA) interactions, Orphan Drug Designation, Fast Track Designation and progress on Phase 3 planning further support a defined path towards registrational developmentNovaBridge to host investor webcast on November 2

    $NBP
  • Borr Drilling Limited - Prospector 5 Rig Incident
    PR·

    Borr Drilling Limited - Prospector 5 Rig Incident

    Borr Drilling Limited (NYSE and OSE: BORR) ("Borr Drilling") confirms that an incident occurred at approximately 20:37 local time on October 24, 2026 involving the Prospector 5 drilling rig while conducting jacking operations offshore Gabon in preparation for a planned drilling campaign. The Prospector 5 is owned and operated by Borr Drilling and is contracted to support BW Energy's drilling operations offshore Gabon. Preliminary information indicates that the rig experienced a punch through event during preload activities, resulting in loss of stability and the subsequent sinking of the rig. Borr Drilling's onshore emergency response team

    $BORR
  • Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
    PR·

    Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

    Longer-term data reflecting nearly 4 years of follow-up show a further reduction in the risk of death from 14% to 37% for those initially treated with Libtayo, despite an 88% crossover from the placebo arm upon recurrence New prospective analyses confirm sustained disease-free survival (DFS) benefit with adjuvant Libtayo, including in patients who are minimal residual disease (MRD) negative at baseline The late-breaking data were presented during a rapid oral session at the European Society for Medical Oncology (ESMO) 2026

    $REGN
  • Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
    PR·

    Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors

    -- 400 mcg/kg chosen as proposed IV RP3D based on 45.5% cORR, 55% uORR and 82% 6-month PFS Kaplan-Meier estimate -- -- Xencor plans to discuss a potential accelerated approval pathway with the FDA in key ccRCC patient subgroups in 1H2027 -- -- Xencor plans global randomized study of monotherapy XmAb819 compared to tivozanib in a post PD-(L)1 and VEGFR TKI ccRCC patient population -- -- Management to host webcast Monday, October 26 at 7:00 a.m. ET / 4:00 a.m. PT -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced updated results from the Phase 1 study of XmAb819

    $XNCR
  • Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
    PR·

    Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule

    JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor, a highly expressed tumor-selective protein in prostate cancer cellsAmong patients with measurable disease in the 50 mg cohort, 75% achieved a complete or partial tumor response in the Phase 1 study77% of patients achieved a confirmed PSA reduction of at least 50%, including nearly half whose PSA levels fell by at least 90%

    $JNJ
  • New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
    PR·

    New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer

    Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in first-line advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) across PD-L1 expression levelsFirst-line treatment options remain an unmet need for patients with KRAS G12C-mutant NSCLC, as most patients do not receive second-line therapy due to the aggressive nature of the diseaseLilly expects first randomized Phase 3 data from SUNRAY-01 in first-line KRAS G12C-mutant NSCLC in the first half of 2027

    $LLY
  • BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
    PR·

    BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

    Pumitamig plus docetaxel demonstrated encouraging responses in squamous and non-squamous non-small cell lung cancer across PD-L1 expression levels with a confirmed objective response rate of 36.7% following progression on or after immunotherapy plus chemotherapyAn early median progression-free survival of 6.9 months was observedSignificant unmet need remains for patients who have progressed on an immunotherapy-containing regimen, with the average progression-free survival below 4 months for standard of care docetaxel Data represent the third global Phase 2 dataset for pumitamig in lung cancer and reinforce its potential to improve outcomes over current standards of care MAINZ, Germany, and

    $BNTX$BMY
  • Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
    PR·

    Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

    Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study anticipated in 2027 200 mg and 600 mg doses have been generally well-tolerated Separate MCD case study described three-year steroid-free remission following budoprutug treatment, supporting further investigation

    $CLYM
  • Teck Provides Update on Highland Valley Copper Operations
    PR·

    Teck Provides Update on Highland Valley Copper Operations

    Teck Resources Limited (TSX:TECK, NYSE:TECK) ("Teck") announced today that strike action by United Steelworkers (USW) Local 7619 has commenced at Teck's Highland Valley Copper (HVC) Operations in B.C. Operations are currently continuing at a reduced capacity. The impact on overall production will depend on the duration of the labour action. Contingency plans are in place with the priority to maintain safety and environmental management during labour action. Teck is committed to reaching a collective agreement that is fair and reasonable for employees and supports the ongoing viability of the operation. Forward-Looking State

    $TECK